amodiaquine has been researched along with 2019 Novel Coronavirus Disease in 8 studies
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.
amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "IPTsc with dihydroartemisinin-piperaquine or artesunate-amodiaquine is a safe and effective approach to reducing malaria parasitaemia, clinical malaria, and related morbidities, and is feasible to implement through programmes delivered by schoolteachers." | 9.69 | Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. ( Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S, 2023) |
| "IPTsc with dihydroartemisinin-piperaquine or artesunate-amodiaquine is a safe and effective approach to reducing malaria parasitaemia, clinical malaria, and related morbidities, and is feasible to implement through programmes delivered by schoolteachers." | 5.69 | Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial. ( Baraka, V; Francis, F; Geertruyden, JV; Gesase, S; Kyaruzi, E; Lusingu, JPA; Madebe, R; Makenga, G; Minja, DTR; Mtove, G; Nakato, S, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jeon, S | 1 |
| Ko, M | 1 |
| Lee, J | 1 |
| Choi, I | 1 |
| Byun, SY | 1 |
| Park, S | 1 |
| Shum, D | 1 |
| Kim, S | 1 |
| Pillaiyar, T | 1 |
| Wendt, LL | 1 |
| Manickam, M | 1 |
| Easwaran, M | 1 |
| Tsanni, A | 1 |
| Ribaudo, G | 3 |
| Yun, X | 3 |
| Ongaro, A | 3 |
| Oselladore, E | 3 |
| Ng, JPL | 3 |
| Haynes, RK | 3 |
| Law, BYK | 3 |
| Memo, M | 3 |
| Wong, VKW | 3 |
| Coghi, P | 3 |
| Gianoncelli, A | 3 |
| Makenga, G | 1 |
| Baraka, V | 1 |
| Francis, F | 1 |
| Nakato, S | 1 |
| Gesase, S | 1 |
| Mtove, G | 1 |
| Madebe, R | 1 |
| Kyaruzi, E | 1 |
| Minja, DTR | 1 |
| Lusingu, JPA | 1 |
| Geertruyden, JV | 1 |
| Olsen, M | 1 |
| Cook, SE | 1 |
| Huang, V | 1 |
| Pedersen, N | 1 |
| Murphy, BG | 1 |
| Ianevski, A | 1 |
| Yao, R | 1 |
| Fenstad, MH | 1 |
| Biza, S | 1 |
| Zusinaite, E | 1 |
| Reisberg, T | 1 |
| Lysvand, H | 1 |
| Løseth, K | 1 |
| Landsem, VM | 1 |
| Malmring, JF | 1 |
| Oksenych, V | 1 |
| Erlandsen, SE | 1 |
| Aas, PA | 1 |
| Hagen, L | 1 |
| Pettersen, CH | 1 |
| Tenson, T | 1 |
| Afset, JE | 1 |
| Nordbø, SA | 1 |
| Bjørås, M | 1 |
| Kainov, DE | 1 |
| Gendrot, M | 1 |
| Duflot, I | 1 |
| Boxberger, M | 1 |
| Delandre, O | 1 |
| Jardot, P | 1 |
| Le Bideau, M | 1 |
| Andreani, J | 1 |
| Fonta, I | 1 |
| Mosnier, J | 1 |
| Rolland, C | 1 |
| Hutter, S | 1 |
| La Scola, B | 1 |
| Pradines, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409] | 231 participants (Actual) | Interventional | 2020-04-24 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for amodiaquine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans | 2021 |
1 trial available for amodiaquine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Effectiveness and safety of intermittent preventive treatment with dihydroartemisinin-piperaquine or artesunate-amodiaquine for reducing malaria and related morbidities in schoolchildren in Tanzania: a randomised controlled trial.
Topics: Amodiaquine; Antimalarials; Artesunate; Child; COVID-19; Drug Combinations; Hemoglobins; Humans; Inc | 2023 |
6 other studies available for amodiaquine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiop | 2020 |
African scientists race to test COVID drugs - but face major hurdles.
Topics: Africa; Amides; Amodiaquine; Artesunate; Atazanavir Sulfate; Carbamates; Clinical Trials as Topic; C | 2021 |
Combining computational and experimental evidence on the activity of antimalarial drugs on papain-like protease of SARS-CoV-2: A repurposing study.
Topics: Amodiaquine; Antimalarials; Antiviral Agents; COVID-19; Drug Repositioning; Humans; Molecular Dockin | 2023 |
Combining computational and experimental evidence on the activity of antimalarial drugs on papain-like protease of SARS-CoV-2: A repurposing study.
Topics: Amodiaquine; Antimalarials; Antiviral Agents; COVID-19; Drug Repositioning; Humans; Molecular Dockin | 2023 |
Combining computational and experimental evidence on the activity of antimalarial drugs on papain-like protease of SARS-CoV-2: A repurposing study.
Topics: Amodiaquine; Antimalarials; Antiviral Agents; COVID-19; Drug Repositioning; Humans; Molecular Dockin | 2023 |
Combining computational and experimental evidence on the activity of antimalarial drugs on papain-like protease of SARS-CoV-2: A repurposing study.
Topics: Amodiaquine; Antimalarials; Antiviral Agents; COVID-19; Drug Repositioning; Humans; Molecular Dockin | 2023 |
Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage.
Topics: Adenosine Triphosphate; Amodiaquine; Angiotensin-Converting Enzyme 2; Animals; Antiviral Agents; Bet | 2020 |
Potential Antiviral Options against SARS-CoV-2 Infection.
Topics: Amodiaquine; Animals; Antiviral Agents; Betacoronavirus; Caco-2 Cells; Cell Line, Tumor; Chlorocebus | 2020 |
Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.
Topics: Amodiaquine; Animals; Antimalarials; Artemether, Lumefantrine Drug Combination; Artemisinins; Betaco | 2020 |